Caricamento...
Nivolumab in relapsed/refractory Hodgkin lymphoma: towards a new treatment strategy?
Chemo-refractory Hodgkin lymphoma (HL), especially after failure of high-dose therapy and autologous stem cell transplantation (ASCT), has a very poor prognosis. Nivolumab, an anti-PD-1 monoclonal antibody, demonstrated durable responses and manageable toxicity in a significant proportion of HL pati...
Salvato in:
| Pubblicato in: | Am J Blood Res |
|---|---|
| Autori principali: | , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
e-Century Publishing Corporation
2021
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8303013/ https://ncbi.nlm.nih.gov/pubmed/34322289 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|